While simvastatin and atorvastatin reduce aortic wall metalloproteinase (MMP) expression and suppress experimental AAA in mice [20]–[22], pravastatin increases human AAA lesion protein levels of MMP–8, MMP–9, and CatB [23]. Here, TYRP1 is linked to triple-A syndrome.